RxDoctor Payments Data

Oji Joseph, MD

Cardiovascular Disease · Lake Wales, FLNPI 1720080096

Payments from drug & device makers

$2,800in general payments, 2019–2025

Across 114 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$412
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$377
  • Medtronic$376
  • AstraZeneca$326
  • Abbott$315
  • Merck$190
  • plus $804 from 15 others

What the payments were for

  • Food & beverage$2,77899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,800 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$3,235,557
Medicare patients
622
Services billed
12,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$164,850
XareltoRivaroxaban52$69,470
Repatha SureclickEvolocumab98$66,291
BrilintaTicagrelor31$39,259
EntrestoSacubitril/Valsartan15$24,417
Repatha SyringeEvolocumab11$11,590
Ranolazine ErRanolazine53$4,475
Prasugrel Hcl18$2,654
ClopidogrelClopidogrel Bisulfate102$1,462
Isosorbide Mononitrate ErIsosorbide Mononitrate105$1,134
Memantine Hcl ErMemantine Hcl11$1,105
Atorvastatin Calcium91$1,067
Amiodarone Hcl37$908
Metoprolol Succinate52$842
Metoprolol Tartrate122$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$164,850151 claims
Johnson & JohnsonXarelto$13$69,47052 claims
AstraZenecaBrilinta$326$39,25931 claims
NovartisEntresto$57$24,41715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Lake Wales

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →